Prostate Cancer Treatment in Hyderabad
Reviewed May 2026 · Dr. Madhav Danthala
Prostate cancer is the textbook example of "more than one right answer" in oncology. For low-risk disease, active surveillance and definitive treatment are both medically defensible. Dr. Madhav Danthala provides treatment planning, hormonal therapy, chemotherapy, and second opinions at KIMS-Sunshine Hospitals, Begumpet, and Peoples Polyclinic, Manikonda.
When to See a Doctor
Early prostate cancer often has no symptoms. Symptomatic presentation usually means more advanced disease. Four signs warrant evaluation.
Dr. Danthala's Approach
Prostate cancer is the cancer where shared decision-making matters most. Three principles shape every consultation.
-
Risk-led planning
Treatment intensity should match disease aggressiveness. Over-treatment of low-risk disease causes harm without benefit.
-
More than one path
For low-risk disease, active surveillance and definitive treatment are both guideline-recommended. The choice depends on the patient's life situation, risk tolerance, and values — not just the biology.
-
Clear, structured communication
Every consult ends with a written summary of options — including the do-nothing-now option — and the trade-offs each path carries.
Treatment Options
Prostate cancer is the cancer in which more than one path is genuinely defensible. Treatment intensity matches risk category, and over-treatment of low-risk disease is itself a form of harm. Below are the major modalities.
Watch closely, treat only if anything changes
For low-risk Gleason 6 disease, active surveillance is guideline-recommended first-line. The protocol involves PSA every 6 months, multiparametric MRI yearly, and confirmatory biopsy if anything changes. Treatment is offered only if the disease shows signs of progression. Many men live a normal life this way for a decade or more, never needing definitive treatment.
Radical prostatectomy — open, laparoscopic, or robotic
For intermediate or high-risk localised disease, radical prostatectomy with pelvic lymph node dissection is one of two equally defensible curative options (the other being radiation). Robotic-assisted approaches have become standard. Nerve-sparing techniques preserve erectile function in selected patients. Recovery from urinary incontinence typically takes weeks to months.
External beam, brachytherapy, SBRT
Intensity-modulated external beam radiation (IMRT) over 4-8 weeks remains the standard. Stereotactic body radiation (SBRT) compresses treatment to 5 sessions with equivalent outcomes for low and intermediate-risk disease. Brachytherapy (low-dose-rate seeds or high-dose-rate temporary) is an option for low-risk disease, often combined with external beam in higher-risk cases. Short-course androgen deprivation is added for intermediate risk.
Hormonal, chemo, PARP, radioligand therapy
For advanced disease, androgen deprivation (GnRH agonists/antagonists) is the foundation, increasingly combined with abiraterone, enzalutamide, apalutamide, or darolutamide. Docetaxel chemotherapy is added for high-volume metastatic disease. PARP inhibitors (olaparib) are an option for BRCA-mutated castration-resistant disease. Lutetium-177 PSMA radioligand therapy is now approved for PSMA-positive metastatic disease.
For prostate cancer, the right plan depends on biology, life expectancy, and the patient's own values. The list above is the menu. The right choice is built with the patient in the room.
Frequently Asked Questions
Should every man get a PSA test?
PSA screening is the most controversial test in oncology. Routine testing is not recommended for all men because it can detect indolent cancers that would never cause harm. Discussion is recommended for men 50 to 70, earlier if family history. BRCA1 and BRCA2 mutations — usually associated with breast and ovarian cancer in women — also raise prostate cancer risk in men, often with more aggressive disease; testing is increasingly recommended for known carriers.
What is active surveillance?
Active surveillance is a real medical option for low-risk prostate cancer (Gleason 6, contained). PSA every 6 months, MRI every year, biopsy if anything changes. Treatment is offered only if the disease progresses. Many men live a normal life this way for a decade or more.
What does Gleason score mean?
Gleason grades how aggressive prostate cancer cells look. Total ranges from 6 (least aggressive) to 10 (most aggressive). Gleason 6 is low-risk and often suitable for active surveillance. Gleason 7 is intermediate-risk. Gleason 8-10 typically warrants prompt treatment.
Should I get a second opinion?
Yes, especially for newly diagnosed low-risk disease. The choice between active surveillance and definitive treatment is the textbook example of more-than-one-right-answer in oncology.
What treatments are available for advanced prostate cancer?
Hormonal therapy (androgen deprivation), often combined with chemotherapy or newer hormonal agents. Targeted therapy with PARP inhibitors for BRCA mutations. Immunotherapy in select cases.
About Dr. Madhav Danthala
Dr. Madhav Danthala is a medical oncologist and hemato-oncologist practising at KIMS-Sunshine Hospitals, Begumpet and Peoples Polyclinic, Manikonda, Hyderabad. His clinical interests span breast, lung, gastrointestinal, gynaecologic, and head & neck cancers, with a focus on subtype-led treatment planning, second opinions, and shared decision-making. He has trained at premier oncology institutes and performed 300+ stem cell transplants.
Trusted guidelines & further reading
- ESMO — Cancer Guides for Patients European Society for Medical Oncology patient guides — freely accessible, evidence-based.
- ASCO / Cancer.Net — Prostate Cancer American Society of Clinical Oncology patient education portal.
- NCI / Cancer.gov — Prostate Cancer US National Cancer Institute clinical treatment summaries.
From our blog
- Active Surveillance: When 'Watch and Wait' Is Right For Gleason 6 disease, doing nothing — for now — is often the right answer. Who's a candidate, what the protocol looks like, and what 15 years of data show.
- The Two-Oncologist Rule: When to Get a Second Opinion Low-risk prostate cancer is the textbook example of more-than-one-right-answer in oncology.
- Your Family's Medical History Is Your Screening Map BRCA mutations raise prostate cancer risk in men too — knowing your family history changes when PSA testing should start.